A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors

Cancer Research

Volumn 65, Issue 13, 2005, Pages 5953-5957

  Tegerstedt, Karin ^a   Lindencrona, Jan Alvar ^a,c   Curcio, Claudia ^b   Andreasson, Kalle ^a   Tullus, Carl ^a   Forni, Guido ^b   Dalianis, Tina ^a   Kiessling, Rolf ^a   Ramqvist, Torbjörn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TURIN   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CAPSID PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC TRANSFECTION; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE NEU; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; TRANSGENIC ANIMAL; TUMOR GROWTH; VACCINATION; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, VIRAL; CANCER VACCINES; CAPSID PROTEINS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; POLYOMAVIRUS; RATS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VACCINATION;

EID: 21344434789     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0335     Document Type: Article

References (19)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177-82.
2. Kiessling R, Well WZ, Herrmann F, et al. Cellular immunity to the Her2/neu protooncogene. Adv Cancer Res 2002;85:101-44.
3. Boggio K, Nicoletti G, Di Carlo E, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her2/neu transgenic mice. J Exp Med 1998;188:589-96.
4. Pannellini T, Forni G, Musiani P. Immunobiology of Her2/neu transgenic mice. Breast Dis 2004;20:33-42.
5. Quaglino E, Iezzi M, Mastini C, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in Her2/neu transgenic mice. Cancer Res 2004;64:2858-64.
6. Richterova Z, Liebl D, Horak M, et al. Caveolae are involved in the trafficking of mouse polyomavirus virions and artificial VP1 pseudocapsids toward cell nuclei. J Virol 2001;75:10880-91.
7. Fried H, Cahan LD, Paulson JC. Polyoma virus recognizes specific sialyligosaccharide receptors on host cells. Virology 1981;109:188-92.
8. Chen XS, Stehle T, Harrison SC. Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. EMBO J 1998;17:3233-40.
9. Piechocki MP, Pilon SA, Kelly C, Wei WZ. Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat. Cell Immunol 2001;212:138-49.
10. Nanni P, Nicoletti G, De Giovanni C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER2/neu transgenic mice. J Exp Med 2001;194:1195-205.
11. + T cell-mediated Her2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004;109:259-64.
12. Tegerstedt K, Andreasson K, Vlastos A, Hedlund KO, Dalianis T, Ramqvist T. Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs. J Gen Virol 2003;84:3443-52.
13. Curcio C, Di Carlo E, Clynes R, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her2/neu carcinomas. J Clin Invest 2003;111:1161-70.
14. Vlastos A, Andreasson K, Tegerstedt K, et al. VP1 pseudocapsids, but not a glutathione-S-transferase VP1 fusion protein, prevent polyomavirus infection in a T-cell immune deficient experimental mouse model. J Med Virol 2003;70:293-300.
15. Pilon SA, Piechocki MP, Wei WZ. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 2001;167:3201-6.
16. Drake DR III, Moser JM, Hadley A, et al. Polyomavirus-infected dendritic cells induce antiviral CD8(+) T lymphocytes. J Virol 2000;74:4093-101.
17. Rollman E, Ramqvist T, Zuber B, et al. Genetic immunization is augmented by murine polyomavirus VP1 pseudocapsids. Vaccine 2003;21:2263-7.
18. Rovero S, Amici A, Carlo ED, et al. DNA vaccination against rat Her2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
19. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.